[go: up one dir, main page]

BRPI0721654B8 - formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso - Google Patents

formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso

Info

Publication number
BRPI0721654B8
BRPI0721654B8 BRPI0721654A BRPI0721654A BRPI0721654B8 BR PI0721654 B8 BRPI0721654 B8 BR PI0721654B8 BR PI0721654 A BRPI0721654 A BR PI0721654A BR PI0721654 A BRPI0721654 A BR PI0721654A BR PI0721654 B8 BRPI0721654 B8 BR PI0721654B8
Authority
BR
Brazil
Prior art keywords
solid dosage
coating
dosage forms
enteric coating
drug release
Prior art date
Application number
BRPI0721654A
Other languages
English (en)
Inventor
Liu Fang
W Basit Abdul
Lizio Rosario
Petereit Hans-Ulrich
Meier Christian
Damm Michael
Original Assignee
Evonik Roehm Gmbh
Roehm Gmbh
Evonik Degussa Gmbh
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh, Roehm Gmbh, Evonik Degussa Gmbh, Evonik Operations Gmbh filed Critical Evonik Roehm Gmbh
Publication of BRPI0721654A2 publication Critical patent/BRPI0721654A2/pt
Publication of BRPI0721654B1 publication Critical patent/BRPI0721654B1/pt
Publication of BRPI0721654B8 publication Critical patent/BRPI0721654B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMAS DE DOSAGEM SÓLIDA COMPREENDENDO UM REVESTIMENTO ENTÉRICO COM LIBERAÇÃO ACELERADA DO FÁRMACO. A presente invenção refere-se a uma forma de dosagem sólida que compreende um revestimento um revestimento interno localizado entre um núcleo que contém um ingrediente farmaceuticamente ativo e um revestimento entérico externo; em que o dito revestimento interno compreende um material polimérico aniônico parcialmente neutralizado e pelo menos um ácido carboxílico que tenha 2 a 16 átomos de carbono, seus sais ou misturas do dito ácido e seu sal; em que o dito revestimento externo compreende um material polimérico aniônico que é menos neutralizado que o material do revestimento interno ou que não é neutralizado.
BRPI0721654A 2007-05-07 2007-05-07 formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso BRPI0721654B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/054398 WO2008135090A1 (en) 2007-05-07 2007-05-07 Solid dosage forms comprising an enteric coating with accelerated drug release

Publications (3)

Publication Number Publication Date
BRPI0721654A2 BRPI0721654A2 (pt) 2013-01-29
BRPI0721654B1 BRPI0721654B1 (pt) 2019-10-22
BRPI0721654B8 true BRPI0721654B8 (pt) 2022-07-05

Family

ID=39410284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721654A BRPI0721654B8 (pt) 2007-05-07 2007-05-07 formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso

Country Status (19)

Country Link
US (2) US9597293B2 (pt)
EP (1) EP2152250B1 (pt)
JP (1) JP5167345B2 (pt)
KR (1) KR101443943B1 (pt)
CN (1) CN101663027B (pt)
AU (1) AU2007352872B2 (pt)
BR (1) BRPI0721654B8 (pt)
CA (1) CA2687130C (pt)
CY (1) CY1122582T1 (pt)
DK (1) DK2152250T3 (pt)
ES (1) ES2759626T3 (pt)
HU (1) HUE046488T2 (pt)
IL (1) IL201557A (pt)
LT (1) LT2152250T (pt)
MX (1) MX2009012030A (pt)
PL (1) PL2152250T3 (pt)
PT (1) PT2152250T (pt)
SI (1) SI2152250T1 (pt)
WO (1) WO2008135090A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
KR101315904B1 (ko) 2005-02-24 2013-10-08 디퓨젼 파마슈티컬즈 엘엘씨 트랜스 카로티노이드, 이들의 합성, 제제화 및 용도
US8293804B2 (en) 2007-04-13 2012-10-23 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
CN101877971A (zh) 2008-01-10 2010-11-03 赢创罗姆有限公司 具有活性物质在结肠中增强的释放的包衣药物或营养制剂
CA2717947C (en) 2008-03-11 2020-07-07 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
KR101891357B1 (ko) * 2010-06-02 2018-08-24 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 경구용 제형
WO2013035081A2 (de) 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
JP5917964B2 (ja) 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
NO2659881T3 (pt) * 2012-04-30 2018-04-28
CU24343B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
US20130295170A1 (en) * 2012-05-03 2013-11-07 Kydes Pharmaceuticals Llc Compositions for control of drug abuse
BR112015002421B1 (pt) * 2012-08-27 2022-01-25 Evonik Röhm Gmbh Composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol, seu uso e seu processo de produção
EP2916828A1 (en) * 2012-11-07 2015-09-16 Nazura Biohealth Inc. Gras enteric coating formulations and methods of making and using same
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
JP6237760B2 (ja) * 2013-02-22 2017-11-29 ゼリア新薬工業株式会社 腸溶錠
JP5934835B2 (ja) * 2013-03-08 2016-06-15 富士フイルム株式会社 腸溶性細粒及び医薬組成物
EP3062776A1 (en) * 2013-10-29 2016-09-07 Tillotts Pharma AG A delayed release drug formulation
EP3236993B1 (en) 2014-12-23 2023-09-13 Theriva Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
MX2018004605A (es) 2015-10-16 2018-11-29 Abbvie Inc Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
WO2018165581A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10524489B2 (en) * 2017-07-12 2020-01-07 Zinpro Corporation Method and composition to control rumen release of cobalt to rumen bacteria for making vitamin B12
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP2021514968A (ja) 2018-02-23 2021-06-17 フィンチ セラピューティクス ホールディングス エルエルシー 微生物関連の免疫療法
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
AU2019250894B2 (en) * 2018-04-12 2024-09-12 Bpsi Holdings Llc Acidifying coatings and disintegration-resistant substrates coated therewith
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662902B1 (en) 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
JP7560483B2 (ja) 2019-05-15 2024-10-02 エボニック オペレーションズ ゲーエムベーハー カプセル充填機を用いて、（メタ）アクリレートコポリマー系のコーティングを有する、充填されたハードシェルカプセルを製造する方法
MX2022000756A (es) 2019-07-19 2022-03-11 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales.
WO2021035665A1 (en) * 2019-08-30 2021-03-04 Dow Global Technologies Llc Polar polyolefin dispersion based seed coating composition
US20220331378A1 (en) 2019-09-13 2022-10-20 Finch Therapeutics Holdings Llc Compositions and methods for treating autism spectrum disorder
US20240226187A9 (en) 2019-10-18 2024-07-11 Finch Therapeutics Holdings Llc Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
WO2021115650A1 (en) 2019-12-11 2021-06-17 Evonik Operations Gmbh Dosage form for use in treating or preventing of a disease
JP2023505714A (ja) 2019-12-11 2023-02-10 エボニック オペレーションズ ゲーエムベーハー アルカリ剤及び腸溶性コーティング層を含む剤形
MX2022007160A (es) 2019-12-11 2022-07-11 Evonik Operations Gmbh Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
TW202140049A (zh) 2020-01-10 2021-11-01 美商芬奇治療控股有限責任公司 用於治療ｂ型肝炎（ｈｂｖ）及ｄ型肝炎（ｈｄｖ）之組合物及方法
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021202806A1 (en) 2020-03-31 2021-10-07 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
WO2022178294A1 (en) 2021-02-19 2022-08-25 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58135807A (ja) 1982-02-05 1983-08-12 Shin Etsu Chem Co Ltd 腸溶性被覆薬剤の製造方法
DE3208791A1 (de) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
ES2298236T3 (es) 2001-01-31 2008-05-16 Evonik Rohm Gmbh Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente.
SK15732003A3 (sk) * 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
CA2444814C (en) 2001-10-24 2009-06-09 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AU2002226955B2 (en) * 2001-11-23 2006-04-27 Allergan Pharmaceuticals International Limited Pharmaceutical dosage form with multiple coatings
JP2005514051A (ja) * 2001-12-21 2005-05-19 ジーン ロジック インコーポレイテッド 胃癌における遺伝子発現プロファイル
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
JP2005538105A (ja) * 2002-07-25 2005-12-15 ファルマシア・コーポレーション 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP2446881B1 (en) * 2003-07-24 2014-04-09 GlaxoSmithKline LLC Orally Dissolving Films
EP1787640A4 (en) 2004-04-30 2012-04-11 Astellas Pharma Inc GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION
US20090110727A1 (en) * 2004-10-12 2009-04-30 Eisai R & D Management Co., Ltd. Extended release compositions of proton pump inhibitors
DE102005007059A1 (de) 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
MX2009001597A (es) 2006-08-18 2009-02-23 Evonik Roehm Gmbh Composicion farmaceutica con liberacion controlada de ingrediente activo para ingredientes activos con buena solubilidad en agua.
CN101877971A (zh) 2008-01-10 2010-11-03 赢创罗姆有限公司 具有活性物质在结肠中增强的释放的包衣药物或营养制剂

Also Published As

Publication number Publication date
WO2008135090A8 (en) 2009-03-05
WO2008135090A1 (en) 2008-11-13
HUE046488T2 (hu) 2020-03-30
BRPI0721654A2 (pt) 2013-01-29
US20130058986A1 (en) 2013-03-07
PL2152250T3 (pl) 2020-06-15
EP2152250A1 (en) 2010-02-17
KR20100016306A (ko) 2010-02-12
CA2687130C (en) 2017-10-03
CN101663027A (zh) 2010-03-03
DK2152250T3 (da) 2019-12-09
CN101663027B (zh) 2013-02-27
CY1122582T1 (el) 2021-01-27
KR101443943B1 (ko) 2014-10-07
JP5167345B2 (ja) 2013-03-21
IL201557A0 (en) 2010-05-31
JP2010526110A (ja) 2010-07-29
PT2152250T (pt) 2019-12-12
US10537530B2 (en) 2020-01-21
MX2009012030A (es) 2010-01-25
IL201557A (en) 2017-06-29
US9597293B2 (en) 2017-03-21
LT2152250T (lt) 2019-12-27
ES2759626T3 (es) 2020-05-11
AU2007352872B2 (en) 2013-03-14
BRPI0721654B1 (pt) 2019-10-22
AU2007352872A1 (en) 2008-11-13
CA2687130A1 (en) 2008-11-13
US20100129446A1 (en) 2010-05-27
SI2152250T1 (sl) 2020-06-30
EP2152250B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
BRPI0721654B8 (pt) formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
BR0013826A (pt) Formas orais de apresentação
BR112014000371A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
BR112016028957A2 (pt) estruturas de residência e métodos relativos
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BRPI0909102A2 (pt) inibidores de pim quinase e métodos de seu uso
BRPI0502466A (pt) forma de dosagem sólida para ingrediente ativo lábil a ácidos
MX2016014921A (es) Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
HRP20191489T1 (hr) Kombinirani sastav
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR112013024585A8 (pt) formas de dosagem farmacêutica de liberação controlada
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
BR112014022214A2 (pt) fenólicos antibacterianos
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
BR112014009438A2 (pt) composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral
BR112013032743A2 (pt) parafuso
WO2014188329A3 (en) Transdermal extended dosing of pramipexole for neurological disorders
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
BR112015014292A2 (pt) compostos tricíclicos para inibição do canal de cftr
BR112018068784A2 (pt) método para o tratamento de leucemia
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: ROEHM GMBH (DE)

B25G Requested change of headquarter approved

Owner name: ROEHM GMBH (DE)

B25A Requested transfer of rights approved

Owner name: EVONIK DEGUSSA GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: EVONIK OPERATIONS GMBH (DE)